Growth Factors of Biomarkers Market
Introduction
Biomarkers have become a crucial component in modern healthcare, playing a vital role in disease diagnosis, drug development, and personalized medicine. The global biomarkers market is witnessing rapid growth, driven by advancements in biotechnology, increased investments in research, and the rising prevalence of chronic diseases such as cancer and cardiovascular conditions.
Market Overview
According tthe latest market research, the global biomarkers market was valued at $38.41 billion in 2018 and is expected treach $190.81 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.1%. This significant expansion can be attributed tthe increasing application of biomarkers in clinical research, diagnostics, and therapeutics.
Key Growth Drivers
1. Rising Prevalence of Chronic Diseases
Chronic diseases such as cancer, diabetes, and cardiovascular disorders are among the leading causes of death worldwide. Biomarkers help in early detection, enabling timely intervention and better treatment outcomes. For instance, cancer biomarkers like PSA (prostate-specific antigen) and HER2 (human epidermal growth factor receptor 2) are widely used in oncology diagnostics.
2. Advancements in Biotechnology and Genomics
Breakthroughs in genomics, proteomics, and molecular biology have revolutionized biomarker discovery. High-throughput screening techniques, next-generation sequencing (NGS), and artificial intelligence (AI)-driven analytics have accelerated biomarker identification, improving diagnostic accuracy and personalized treatment strategies.
3. Increased Investments in Research and Development (R&D)
Governments and private organizations are heavily investing in biomarker research tdevelop innovative diagnostic tools and targeted therapies. The pharmaceutical and biotechnology sectors are leveraging biomarkers tenhance drug development efficiency and reduce clinical trial costs.
4. Growing Demand for Personalized Medicine
Biomarkers are at the forefront of personalized medicine, enabling tailored treatment approaches based on individual genetic profiles. This trend is particularly prominent in oncology, where precision medicine is transforming cancer care by identifying patients most likely tbenefit from specific treatments.
Market Segmentation
The biomarkers market is segmented based on:
- Type: Safety biomarkers, efficacy biomarkers, and validation biomarkers
- Application: Drug discovery & development, diagnostics, personalized medicine, and disease risk assessment
- End Users: Pharmaceutical & biotechnology companies, research institutions, and diagnostic labs
Regional Insights
1. North America
North America dominates the biomarkers market, driven by a strong healthcare infrastructure, high R&D spending, and the presence of leading pharmaceutical companies. The U.S. leads in biomarker-based drug development and regulatory approvals.
2. Europe
Europe holds a significant market share, with increasing government initiatives supporting biomarker research. Countries like Germany, the U.K., and France are at the forefront of precision medicine and biomarker-driven diagnostics.
3. Asia-Pacific
The Asia-Pacific region is witnessing the fastest growth, fueled by rising healthcare expenditure, expanding biotech industries, and growing awareness about personalized medicine. China and India, in particular, are emerging as key players in biomarker research.
Challenges and Future Outlook
Despite the promising growth, the biomarkers market faces challenges such as:
- High costs of biomarker discovery and validation
- Regulatory complexities and approval delays
- Limited standardization in biomarker testing
Conclusion
The biomarkers market is on a remarkable growth trajectory, transforming disease diagnostics, drug development, and patient care. With ongoing R&D, technological innovations, and global healthcare initiatives, biomarkers will continue tshape the future of personalized medicine and precision healthcare.
ATTRIBUTE DETAILS
Study Period - 2015-2026
Base Year - 2018
Forecast Period - 2019-2026
Historical Period - 2015-2017
Unit - Value (USD billion)
By Indication
- Oncology
- Cardiology
- Neurology
- Others
- Pharmaceutical & Biotechnology Companies
- Diagnostics & Research Laboratories
- Hospitals & Specialty Clinics
- Others
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. New Product Launches, by Key Market Players
- 4.2. Prevalence by Disease Indication, By Key Countries/ Region, 2018
- 4.3. Incidence of Cancer, By Key Countries/ Key Region,2018
- 4.4. Key industry Developments - Mergers, Acquisitions and Partnerships
- 4.5. Overview of Biomarkers In Personalized Medicine
- 5. Global Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Indication
- 5.2.1. Oncology
- 5.2.2. Cardiology
- 5.2.3. Neurology
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast – By End User
- 5.3.1. Pharmaceutical & Biotechnology Companies
- 5.3.2. Diagnostics & Research Laboratories
- 5.3.3. Hospitals & Specialty Clinics
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
- 6. North America Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Indication
- 6.2.1. Oncology
- 6.2.2. Cardiology
- 6.2.3. Neurology
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast – By End User
- 6.3.1. Pharmaceutical & Biotechnology Companies
- 6.3.2. Diagnostics & Research Laboratories
- 6.3.3. Hospitals & Specialty Clinics
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Indication
- 7.2.1. Oncology
- 7.2.2. Cardiology
- 7.2.3. Neurology
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast – By End User
- 7.3.1. Pharmaceutical & Biotechnology Companies
- 7.3.2. Diagnostics & Research Laboratories
- 7.3.3. Hospitals & Specialty Clinics
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia Pacific Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Indication
- 8.2.1. Oncology
- 8.2.2. Cardiology
- 8.2.3. Neurology
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast – By End User
- 8.3.1. Pharmaceutical & Biotechnology Companies
- 8.3.2. Diagnostics & Research Laboratories
- 8.3.3. Hospitals & Specialty Clinics
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
- 9. Latin America Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Indication
- 9.2.1. Oncology
- 9.2.2. Cardiology
- 9.2.3. Neurology
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast – By End User
- 9.3.1. Pharmaceutical & Biotechnology Companies
- 9.3.2. Diagnostics & Research Laboratories
- 9.3.3. Hospitals & Specialty Clinics
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
- 10. Middle East & Africa Biomarkers Market Analysis, Insights and Forecast, 2015-2026
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Indication
- 10.2.1. Oncology
- 10.2.2. Cardiology
- 10.2.3. Neurology
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast – By End User
- 10.3.1. Pharmaceutical & Biotechnology Companies
- 10.3.2. Diagnostics & Research Laboratories
- 10.3.3. Hospitals and Specialty Clinics
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 10.4.1. GCC Countries
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2018)
- 11.3. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.3.1. F. Hoffmann-La Roche Ltd.
- 11.3.1.1. Overview,
- 11.3.1.2. Products & services,
- 11.3.1.3. SWOT analysis,
- 11.3.1.4. Recent developments,
- 11.3.1.5. strategies,
- 11.3.1.6. financials (based on availability)
- 11.3.2. Abbott
- 11.3.2.1. Overview,
- 11.3.2.2. Products & services,
- 11.3.2.3. SWOT analysis,
- 11.3.2.4. Recent developments,
- 11.3.2.5. strategies,
- 11.3.2.6. financials (based on availability)
- 11.3.3. Thermo Fisher Scientific
- 11.3.3.1. Overview,
- 11.3.3.2. Products & services,
- 11.3.3.3. SWOT analysis,
- 11.3.3.4. Recent developments,
- 11.3.3.5. strategies,
- 11.3.3.6. financials (based on availability)
- 11.3.4. Bio-Rad Laboratories, Inc
- 11.3.4.1. Overview,
- 11.3.4.2. Products & services,
- 11.3.4.3. SWOT analysis,
- 11.3.4.4. Recent developments,
- 11.3.4.5. strategies,
- 11.3.4.6. financials (based on availability)
- 11.3.5. CENTOGENE N.V.
- 11.3.5.1. Overview,
- 11.3.5.2. Products & services,
- 11.3.5.3. SWOT analysis,
- 11.3.5.4. Recent developments,
- 11.3.5.5. strategies,
- 11.3.5.6. financials (based on availability)
- 11.3.6. Axon Medchem
- 11.3.6.1. Overview,
- 11.3.6.2. Products & services,
- 11.3.6.3. SWOT analysis,
- 11.3.6.4. Recent developments,
- 11.3.6.5. strategies,
- 11.3.6.6. financials (based on availability)
- 11.3.7. Sino Biological Inc.
- 11.3.7.1. Overview,
- 11.3.7.2. Products & services,
- 11.3.7.3. SWOT analysis,
- 11.3.7.4. Recent developments,
- 11.3.7.5. strategies,
- 11.3.7.6. financials (based on availability)
- 11.3.8. R&D System
- 11.3.8.1. Overview,
- 11.3.8.2. Products & services,
- 11.3.8.3. SWOT analysis,
- 11.3.8.4. Recent developments,
- 11.3.8.5. strategies,
- 11.3.8.6. financials (based on availability)
- 11.3.9. BioVision Inc.
- 11.3.9.1. Overview,
- 11.3.9.2. Products & services,
- 11.3.9.3. SWOT analysis,
- 11.3.9.4. Recent developments,
- 11.3.9.5. strategies,
- 11.3.9.6. financials (based on availability)
- 11.3.10. Myriad RBM
- 11.3.10.1. Overview,
- 11.3.10.2. Products & services,
- 11.3.10.3. SWOT analysis,
- 11.3.10.4. Recent developments,
- 11.3.10.5. strategies,
- 11.3.10.6. financials (based on availability)
- 11.3.11. Other Prominent Players
- 11.3.11.1. Overview,
- 11.3.11.2. Products & services,
- 11.3.11.3. SWOT analysis,
- 11.3.11.4. Recent developments,
- 11.3.11.5. strategies,
- 11.3.11.6. financials (based on availability)
- 12. Strategic Recommendation
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook